UNSPSC 51333601: Risperidone

This classification denotes an antipsychotic agent with the molecular formula C23H27FN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L6UH7ZF8HC, chemically known as 4h-pyrido(1,2-a)pyrimidin-4-one, 6,7,8,9-tetrahydro-3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-2-methyl- but generally known as risperidone, which bears US NIH Compound Identifier 5073. European Medicines Agency schedules Risperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10335MIG.

UNSPSC 51333601 Risperidone is a Commodity code that in recent state and local procurement activity covers pharmaceutical products including naloxone, over-the-counter medications, and generic multi-source drugs procured through competitive bidding and cooperative purchasing arrangements. State and local governments soliciting under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The scope of work spans direct procurement of finished pharmaceutical inventory for community health initiatives, competitive bidding for annual supply contracts with quarterly or as-needed deliveries, and participation in cooperative purchasing networks that negotiate manufacturer pricing and establish wholesaler distribution channels. Issuing bodies include standalone county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperatives administering contracts on behalf of member states and local entities (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participating jurisdictions).

Recent activity includes Seminole County's IFB60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline; the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, requesting vendor capability information for direct-to-manufacturer prescription programs; and MMCAP's S1070000015802 RFP, posted January 20, 2026 with a March 26, 2026 response deadline, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers. Geographic activity spans Florida, Texas, Minnesota, and Oregon. Procurement vehicles include traditional competitive bidding (IFB), market-intelligence RFIs, and cooperative purchasing RFPs with multi-year terms. Contract administration typically requires cGMP and Drug Supply Chain Security Act compliance, E-Verify certification, comprehensive insurance including commercial general liability and professional liability coverage, and adherence to federal environmental and procurement regulations when FEMA or other federal funding is involved.